PCRX - Pacira BioSciences reports net product sales of $57.5M
- Health solutions company Pacira BioSciences ( NASDAQ: PCRX ) said its November preliminary unaudited net product sales stood at $57.5M.
- The company's net product sales include the products Exparel, Zilretta and the iovera system.
- Exparel net product sales were $46M, compared with $46.5M Y/Y. Zilretta net product sales were $10M, and iovera net product sales were $1.5M.
- The company said it is not providing 2022 revenue or gross margin guidance, considering the continued uncertainty around labor shortages, COVID-19 and the pace of recovery for the elective surgery market.
- Source: Press Release
For further details see:
Pacira BioSciences reports net product sales of $57.5M